Calporta Therapeutics

Calporta Therapeutics aims to provide treatment for Niemann-Pick type C disease. The company's products include selective small molecule agonists of transient receptor potential cation channels, used to treat lysosomal storage diseases caused by mutations, enabling patients to receive advanced treatment for their condition and recover more quickly.